Immunai and AstraZeneca Collaborate to Optimize Oncology Clinical Trials Using AI-driven Immune Mapping
Immunai, a New York-based AI biotech company, has entered a multi-year collaboration with AstraZeneca to optimize oncology clinical trials. This partnership will use Immunai’s proprietary AMICA platform and Immunodynamics Engine (IDE)—technologies combining multi-omic single-cell data and advanced AI models of the immune system—to improve trial design and clinical decision-making.
Under the agreement, Immunai will receive $18 million for the initial phase, focusing on clinical trial optimization, including:
- Dose selection
- Mechanism of action elucidation
- Patient responder vs. non-responder analysis
- Biomarker identification
This collaboration builds on their previous work with AstraZeneca, which began in 2022, providing data-driven insights into several oncology programs. AstraZeneca has the option to extend the collaboration beyond the initial phase.
Immunai’s AMICA platform—the Annotated Multi-Omic Immune Cell Atlas—is claimed to be the world’s largest single-cell immune knowledge base, containing data from:
- Tens of millions of cells across hundreds of disease settings
- 5,000+ studies, including 350+ single-cell studies
- 80+ immune cell types across 500+ diseases
- 100,000+ patient samples
The IDE leverages this vast dataset to guide immune-modulating drug discovery by identifying patient subgroups, validating therapeutic hypotheses, and discovering new biomarkers. The platform integrates both public and proprietary datasets, combining functional genomics and dynamic data engineering for single-cell profiling and multiplexed perturbation studies.
Immunai has raised over $270 million in total funding, including a $215 million Series B round in 2021. The funds are fueling expansion beyond immuno-oncology into areas like autoimmune, cardiovascular, and neurological diseases.
Topics: Startups & Deals
